MétaCan
Menu
Back to cohort
Record W2570216110

Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.

2007· article· en· W2570216110 on OpenAlexaff
Malcolm Ranson, Emma Dean, Tim Ward, Jeff Cummings, L Robson, Jon P. Durkin, Jacques Jolivet, Duncan I. Jodrell, Caroline Dive

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMolecular Biology Techniques and Applications
Canadian institutionsAegera Therapeutics (Canada)
Fundersnot available
KeywordsXIAPApoptosisProgrammed cell deathInhibitor of apoptosisPharmacologyMedicineCancerBiologyCaspaseCancer researchInternal medicine
DOInot available

Abstract

fetched live from OpenAlex

C163 The X-linked inhibitor of apoptosis protein (XIAP) is a potent anti-apoptotic protein and is widely up-regulated in a variety of cancer cell lines. AEG35156 (Aegera Therapeutics Inc) is a second generation antisense oligonucleotide targeting human XIAP and pre-clinical studies indicate that AEG35156 will induce tumour cell death both as a single agent and in combination with radiotherapy or chemotherapy. AEG35156 has been administered as a 7-day or 3-day continuous infusion every 3 weeks, and as a weekly 2-hour infusion (ongoing). The primary objectives of these Phase I trials were to establish the Maximum Tolerated Dose (MTD) and toxicity profile. Secondary objectives included the evaluation of three potential plasma pharmacodynamic biomarkers of apoptosis, which may be used in conjuction with measurements of the direct impact of AEG35156 on XIAP mRNA and protein, to identify optimal biological doses and schedules of AEG35156 for future studies. 1) An M30 ELISA detects a caspase-cleaved fragment of the epithelial cell protein cytokeratin 18 (CK18) as a selective marker of apoptosis 2) An M65 ELISA detects both intact and caspase-cleaved CK18 as markers of apoptotic and non-apoptotic cell death; and 3) An ELISA assay for the quantification of circulating nucleosomal DNA (nDNA).
 Plasma samples were collected from treated patients, initially with epithelial tumours and subsequently from all types of advanced refractory cancer, at multiple time points during treatment. Samples have been analysed from 24 patients in the 7-day infusion protocol, 16 patients in the 3-day protocol, and 20 patients in the 2-hour protocol. The biomarker profiles showed a temporal association with drug infusion; a significant rise in biomarker value from baseline typically occurred before day 4 of treatment. Generally there was a good correlation between M30, M65 and nDNA results, with the best agreement between M65 & nDNA. Some patients have a biomarker signature suggestive of disease progression. The most commonly occurring drug-related toxicities were reversible transaminitis and thrombocytopenia. . Longitudinal plots of liver transaminases and M65 antigen levels revealed that patients who had an elevation in liver transaminases also had a significant temporally associated rise in M65 antigen levels. Such increases in circulating M65 antigen levels during or following treatment in patients with non-epithelial, non-CK18 expressing tissues suggest that ELISAs may also detect non-tumour tissue toxicity. In conclusion, these emerging results from the XIAP trials suggest three pharmacodynamic biomarkers of apoptosis may have clinical potential as indicators of pathological progression, and can also yield information on both tumour and non-tumour response to AEG35156. Further studies are required to assess the correlation with clinical outcome.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.057
GPT teacher head0.422
Teacher spread0.365 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicMolecular Biology Techniques and ApplicationsFrench-language works237,207